CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients

Viral infections, such as with cytomegalovirus (CMV), remain a major risk factor for mortality and morbidity of transplant recipients because of their requirement for lifelong immunosuppression (IS). Antiviral drugs often cause toxicity and sometimes fail to control disease. Thus, regeneration of th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular therapy 2021-01, Vol.29 (1), p.32-46
Hauptverfasser:	Amini, Leila, Wagner, Dimitrios Laurin, Rössler, Uta, Zarrinrad, Ghazaleh, Wagner, Livia Felicitas, Vollmer, Tino, Wendering, Désirée Jacqueline, Kornak, Uwe, Volk, Hans-Dieter, Reinke, Petra, Schmueck-Henneresse, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	adoptive T-cell-therapy Biotechnology & Applied Microbiology CMV CRISPR-Cas Systems CRISPR-Cas9 Disease Resistance - immunology Drug Resistance Gene Editing Genetic Engineering Genetics & Heredity Humans immunosuppression Immunosuppressive Agents - pharmacology immunotherapy Immunotherapy, Adoptive Life Sciences & Biomedicine Medicine, Research & Experimental Original Research & Experimental Medicine Science & Technology solid-organ-transplantation T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - metabolism Tacrolimus - pharmacology Transplant Recipients vector-free gene-editing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!